Enlivex Amends Lind Note: Principal Jumps to $19.2M, Conversion Price Set at 80% of Market with $1.50 Floor Reserve
ENLV is trading near its 52-week low of $1.8 (6.7% above the low).
Summary
Enlivex amended its $21M convertible note with Lind Global, increasing the principal to $19.2M, extending maturity, and setting a conversion price at 80% of market with a $1.50 reserve floor — implying massive potential dilution.
Key Events · Financing and Capital Events · ENLV
-
Principal Increased to $19.2M
The outstanding principal was raised from ~$16.3M to $19.2M, a 17.5% increase, in consideration for the amendment terms.
-
Conversion Price Tied to 80% of Market
The conversion price is now the lower of $40.37625 or 80% of the average of the three lowest daily VWAPs over the 20 trading days prior to conversion notice. At current prices, this implies a conversion price around $1.54, deeply dilutive.
-
25M Share Reserve with $1.50 Floor
The company must reserve 25M ordinary shares for conversion, assuming a $1.50 conversion price. This implies potential issuance of up to 12.8M shares, or ~76% of the current outstanding, if fully converted at that floor.
-
Maturity Extended Indefinitely
Monthly payments reduced from $2.3M to $1.2M, with the holder able to waive payments and extend maturity month-by-month. The original March 2027 maturity is effectively replaced by a flexible schedule.
Analysis · ENLV · Life Sciences
Enlivex restructured its $21M convertible note with Lind Global, increasing the outstanding principal by 17.5% to $19.2M and extending the maturity indefinitely via reduced monthly payments. The conversion price is now the lower of $40.38 or 80% of the three lowest VWAPs over 20 days — a deeply dilutive formula at current prices. The company must reserve 25M shares for conversion, assuming a $1.50 floor, which implies potential issuance of up to 12.8M shares, or roughly 76% of the current outstanding. The market cap default was waived, but interest now accrues at 10% whenever the market cap is below $75M — a near certainty given the current ~$32M market cap. This amendment signals acute cash constraints and a willingness to accept highly dilutive terms to avoid default.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.3M. The 52-week trading range was $1.80 to $31.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.